Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,041,800 shares of the company’s stock after selling 125,098 shares during the period. New York State Common Retirement Fund’s holdings in Ginkgo Bioworks were worth $1,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DNA. Powell Investment Advisors LLC lifted its holdings in shares of Ginkgo Bioworks by 100.0% in the 4th quarter. Powell Investment Advisors LLC now owns 45,000 shares of the company’s stock valued at $76,000 after buying an additional 22,500 shares during the period. Daiwa Securities Group Inc. lifted its holdings in Ginkgo Bioworks by 32.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 62,943 shares of the company’s stock valued at $106,000 after acquiring an additional 15,396 shares during the period. Cerity Partners LLC boosted its position in Ginkgo Bioworks by 5.3% in the 4th quarter. Cerity Partners LLC now owns 209,613 shares of the company’s stock worth $354,000 after purchasing an additional 10,472 shares in the last quarter. Smith Salley & Associates grew its stake in shares of Ginkgo Bioworks by 100.0% during the 4th quarter. Smith Salley & Associates now owns 24,000 shares of the company’s stock worth $41,000 after purchasing an additional 12,000 shares during the period. Finally, Prime Capital Investment Advisors LLC purchased a new position in shares of Ginkgo Bioworks during the 4th quarter valued at approximately $37,000. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock opened at $0.89 on Thursday. The stock has a market capitalization of $1.92 billion, a P/E ratio of -1.90 and a beta of 1.42. The company’s fifty day moving average price is $1.05 and its 200 day moving average price is $1.30. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $0.74 and a 1 year high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last announced its earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The company had revenue of $34.76 million during the quarter, compared to analyst estimates of $40.37 million. During the same quarter last year, the business earned ($0.04) EPS. The firm’s revenue for the quarter was down 64.6% compared to the same quarter last year. Sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current year.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Mark E. Dmytruk sold 47,806 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total value of $40,157.04. Following the transaction, the insider now owns 925,400 shares in the company, valued at $777,336. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Mark E. Dmytruk sold 51,169 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total value of $53,727.45. Following the completion of the sale, the insider now directly owns 865,079 shares in the company, valued at $908,332.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark E. Dmytruk sold 47,806 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the transaction, the insider now directly owns 925,400 shares in the company, valued at $777,336. The disclosure for this sale can be found here. Insiders own 15.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on DNA shares. The Goldman Sachs Group lowered their price target on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating on the stock in a report on Monday, January 22nd. TD Cowen cut their price target on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.